文献速递慢性肾脏病遗传性与小管间质肾病

成纤维细胞生长因子23与常染色体显性多囊肾病进展

Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-07-13

本研究在HALT-PKD A和B研究中检测1002例常染色体显性多囊肾病患者的基线血清完整FGF23水平,分析其与eGFR下降、身高调整总肾脏体积百分比变化及复合终点(eGFR下降50%、ESRD或死亡)的关联。结果显示较高FGF23与肾功能下降更快、肾脏体积增长更多及复合终点风险升高相关,但将FGF23加入模型并未显著改善对快速肾功能下降的预测。

要点

  • 较高血清FGF23与ADPKD患者eGFR下降更快独立相关。
  • 较高FGF23与身高调整总肾脏体积增长更多相关。
  • FGF23未显著改善对快速肾功能下降的预测。

核心结论

  • 较高血清FGF23浓度与ADPKD患者肾功能下降、身高调整总肾脏体积百分比增加及死亡相关。
  • FGF23并未实质改善对快速肾功能下降的预测。

研究设计与样本

  • 测量HALT-PKD研究A(n=540,平均eGFR 91±17 ml/min/1.73 m2)和B(n=462,平均eGFR 48±12 ml/min/1.73 m2)共1002例参与者的基线血清完整FGF23水平。
  • 采用线性混合模型和Cox比例风险模型检验FGF23与eGFR下降、身高调整总肾脏体积百分比变化及复合终点(eGFR下降50%、ESRD或死亡)的关联。

主要发现

  • HALT-PKD A中完整FGF23中位数(IQR)为44(33-56)pg/ml,B中为69(50-93)pg/ml。
  • 调整模型中,A研究FGF23最高四分位组年化eGFR下降为-3.62(95%CI -4.12至-3.12)ml/min/1.73 m2,最低四分位组为-2.51(95%CI -2.71至-2.30)ml/min/1.73 m2,趋势P<0.001。
  • 调整模型中,B研究FGF23最高四分位组年化eGFR下降为-3.74(95%CI -4.14至-3.34)ml/min/1.73 m2,最低四分位组为-2.78(95%CI -2.92至-2.63)ml/min/1.73 m2,趋势P<0.001。
  • A研究中较高FGF23四分位与身高调整总肾脏体积纵向百分比增加更大相关(最高四分位组6.76,95%CI 5.57至7.96;最低四分位组6.04,95%CI 5.55至6.54;趋势P=0.03)。
  • B研究中最高FGF23四分位组相比最低四分位组复合终点风险升高(HR 3.11,95%CI 1.84至5.25)。

临床怎么用

  • 在ADPKD患者中,血清FGF23升高提示肾功能下降和肾脏体积增长风险更高。
  • FGF23不宜单独用于预测快速肾功能下降,需结合其他临床指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Increases in fibroblast growth factor 23 precede kidney function decline in autosomal dominant polycystic kidney disease; however, the role of fibroblast growth factor 23 in autosomal dominant polycystic kidney disease has not been well characterized. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: We measured intact fibroblast growth factor 23 levels in baseline serum samples from 1002 participants in the HALT-PKD Study A (n=540; mean eGFR =91±17 ml/min per 1.73 m2) and B (n=462; mean eGFR =48±12 ml/min per 1.73 m2). We used linear mixed and Cox proportional hazards models to test associations between fibroblast growth factor 23 and eGFR decline, percentage change in height-adjusted total kidney volume, and composite of time to 50% reduction in eGFR, onset of ESRD, or death. RESULTS: Median (interquartile range) intact fibroblast growth factor 23 was 44 (33-56) pg/ml in HALT-PKD Study A and 69 (50-93) pg/ml in Study B. In adjusted models, annualized eGFR decline was significantly faster in the upper fibroblast growth factor 23 quartile (Study A: quartile 4, -3.62; 95% confidence interval, -4.12 to -3.12 versus quartile 1, -2.51; 95% confidence interval, -2.71 to -2.30 ml/min per 1.73 m2; P for trend <0.001; Study B: quartile 4, -3.74; 95% confidence interval, -4.14 to -3.34 versus quartile 1, -2.78; 95% confidence interval, -2.92 to -2.63 ml/min per 1.73 m2; P for trend <0.001). In Study A, higher fibroblast growth factor 23 quartiles were associated with greater longitudinal percentage increase in height-adjusted total kidney volume in adjusted models (quartile 4, 6.76; 95% confidence interval, 5.57 to 7.96 versus quartile 1, 6.04; 95% confidence interval, 5.55 to 6.54; P for trend =0.03). In Study B, compared with the lowest quartile, the highest fibroblast growth factor 23 quartile was associated with elevated risk for the composite outcome (hazard ratio, 3.11; 95% confidence interval, 1.84 to 5.25). Addition of fibroblast growth factor 23 to a model of annualized decline in eGFR≥3.0 ml/min per 1.73 m2 did not improve risk prediction. CONCLUSIONS: Higher serum fibroblast growth factor 23 concentration was associated with kidney function decline, height-adjusted total kidney volume percentage increase, and death in patients with autosomal dominant polycystic kidney disease. However, fibroblast growth factor 23 did not substantially improve prediction of rapid kidney function decline.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Chonchol M, Gitomer B, Isakova T, et al. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017. PMID: 28705885. doi:10.2215/CJN.12821216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。